AltaThera Pharmaceuticals is a pioneer in cardiovascular medicine, based in Chicago, Illinois, with a team operating across the United States. We develop and commercialize hospital-use intravenous therapies that personalize cardiovascular treatment for patients with serious cardiac arrhythmias — conditions that are life-threatening, costly to manage, and too often undertreated.
Our work is grounded in a belief that the right therapy, delivered the right way, at the right time, can fundamentally change outcomes. That conviction — and a commitment to lead a new era of innovative therapies for cardiac arrhythmia and critical conditions — shapes everything we do, from how we develop our science to how we support the physicians and health systems that rely on our therapies.
Our mission is to pioneer therapies that address critical gaps in cardiac care, by combining deep clinical insight, scientific rigor, and agile execution to deliver improved patient outcomes and elevate standards of care.
At the heart of what we do is one of medicine’s most urgent and under-served challenges: cardiac arrhythmia. Every therapy we develop, every study we support, and every patient we reach reflects three interconnected commitments.
Intravenous therapy can give physicians faster, more actionable information about a patient’s response to treatment.
Our science is built on pharmacometric modeling that accounts for individual patient physiology — enabling dosing decisions informed by data, not approximation.
By transitioning appropriate care from inpatient to outpatient settings, we reduce length of stay, improve patient experience, and free hospital resources for those who need them most.
